Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Dizziness, Dry skin, Eczema, Erythema
Clinical narrative: Related symptoms if any separated by commas; Lightheaded; Raised itchy places; Gets a taste in her mouth; Eczema; back has some redness; covid shot site is still red and raised; covid shot site is still red and raised; Eczema; dry skin; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 2021SA408737 (Mfr report number).  A 71 year-old female patient received bnt162b2 (BNT162B2), administration date 2021 as dose number unknown, single for covid-19 immunisation; dupilumab (DUPIXENT), subcutaneous, administration date Oct2021 (Batch/Lot number: unknown) as 300 mg qow for dermatitis atopic. Relevant medical history included: "Historical Condition (Drug Hypersensitivity)" (ongoing); "Historical Condition (Rhinitis allergic)" (ongoing); "Historical Condition (Depression)" (ongoing); "Historical Condition (neoplasm malignant)" (ongoing); "Historical Condition (gastroesophageal reflux disease)" (ongoing); "Historical Condition (Menopausal disorder)" (ongoing); "Historical Condition (Multiple sclerosis)" (unspecified if ongoing); "Historical Condition (Metabolic disorder)" (ongoing); "Historical Condition (Neoplasm skin)" (ongoing); "Historical Condition (Iodine allergy)" (ongoing); "Historical Condition (Rubber sensitivity)" (ongoing); "Historical Condition (Migraine)" (ongoing); "Historical Condition (Food allergy)" (ongoing); "Historical Condition (Milk allergy)" (ongoing); "Allergies: banana" (unspecified if ongoing), notes: Allergies: banana; "Allergies: cantaloupe" (unspecified if ongoing), notes: Allergies: cantaloupe; "Allergies: egg derived" (unspecified if ongoing), notes: Allergies: egg derived; "Allergies: iodine" (unspecified if ongoing), notes: Allergies: iodine; "Allergies: kiwi" (unspecified if ongoing), notes: Allergies:  kiwi; "Allergies: latex" (unspecified if ongoing), notes: Allergies: latex; "Allergies: melon" (unspecified if ongoing), notes: Allergies: melon; "Allergies: milk" (unspecified if ongoing), notes: Allergies: milk; "Allergies: penicillins" (unspecified if ongoing), notes: Allergies: penicillins; "Allergies: shellfish derived" (unspecified if ongoing), notes: Allergies: shellfish derived; "atopic dermatitis" (unspecified if ongoing). Concomitant medication(s) included: COPAXONE; MAXEPA; MULTIVITAMINS [VITAMINS NOS]; PANTOTHENIC ACID CALCIUM; PREVNAR; QUERCETIN; SHINGRIX; VITAMIN D3; FLUZONE HIGH DOSE QUADRIVALENT; PNEUMOVAX. Past drug history included: Amoxicillin, reaction(s): "Allergies: amoxicillin", notes: Allergies: amoxicillin; Ceclor, reaction(s): "Allergies: ceclor", notes: Allergies: ceclor; Cefaclor, reaction(s): "Allergies: cefaclor", notes: Allergies: cefaclor; Cephalosporins, reaction(s): "Allergies: cephalosporins", notes: Allergies: cephalosporins; Cipro, reaction(s): "Allergies: cipro", notes: Allergies: cipro; Quinolones, reaction(s): "Allergies: quinolones", notes: Allergies: quinolones.  The following information was reported: ECZEMA (non-serious), PRURITUS (non-serious) all with onset 2021, outcome "unknown" and all described as "Eczema"; ERYTHEMA (non-serious) with onset 2021, outcome "unknown", described as "back has some redness"; INJECTION SITE SWELLING (non-serious), INJECTION SITE ERYTHEMA (non-serious) all with onset 2021, outcome "not recovered" and all described as "covid shot site is still red and raised"; DRY SKIN (non-serious) with onset 2021, outcome "unknown", described as "dry skin"; ABDOMINAL DISCOMFORT (non-serious), outcome "unknown", described as "Related symptoms if any separated by commas"; DIZZINESS (non-serious), outcome "unknown", described as "Lightheaded"; PRURITUS (non-serious), outcome "unknown", described as "Raised itchy places"; TASTE DISORDER (non-serious), outcome "unknown", described as "Gets a taste in her mouth". The action taken for dupilumab was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.